← Eichor
Condition: Irae Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Irae

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

The Effect of Serum Ferritin in irAE
NA · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06702566Food Intervention to Reduce Immunotherapy ToXicity
NA · 1 location(s) · Universitair Ziekenhuis Brussel · NCT05832606Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy
Phase N/A · 1 location(s) · Taipei Veterans General Hospital, Taiwan · NCT06461780SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)
Phase 2 · 3 location(s) · Queensland Centre for Gynaecological Cancer · NCT06278857Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
Phase 2 · 2 location(s) · Sun Yat-sen University · NCT07644897Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer
Phase N/A · 1 location(s) · Xijing Hospital · NCT06613165A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Epi
Phase N/A · 3 location(s) · Oxford Biodynamics Inc. · NCT06635954A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their
Phase N/A · 5 location(s) · Hospices Civils de Lyon · NCT03989323Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype
Phase N/A · 1 location(s) · Lucie Heinzerling · NCT05700565Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis
Phase 2 · 1 location(s) · AHS Cancer Control Alberta · NCT06860542Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository
Phase 1/Phase 2 · 2 location(s) · Brigham and Women's Hospital · NCT06789601Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors
Phase N/A · 1 location(s) · Institut Mutualiste Montsouris · NCT05799898Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)
Phase 2 · 1 location(s) · AHS Cancer Control Alberta · NCT05663775Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in
Phase 2 · 1 location(s) · Yuanquan Yang · NCT06470971Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis
Phase 2 · 1 location(s) · Tom Appleton · NCT06037811Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoi
NA · 1 location(s) · Centre Hospitalier Universitaire, Amiens · NCT05813418
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.